Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803299 | 0.88 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL13201180 | 0.88 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL13196701 | 0.88 | DRD2 (0.41) | DRD2DRD3FUCA1SIGMAR1 | |
| SCHEMBL6309643 | 0.86 | DRD2 (0.47) | DRD2DRD3FUCA1GRIN2B | |
| SCHEMBL5811952 | 0.84 | DRD2 (0.42) | DRD2DRD3FUCA1SIGMAR1LMNA | |
| SCHEMBL6312037 | 0.82 | KDM1A (0.46) | DRD2DRD3FUCA1SIGMAR1GRIN2B | |
| SCHEMBL25391591 | 0.78 | FUCA1 (0.45) | DRD2DRD3FUCA1SIGMAR1GRIN2B | |
| SCHEMBL20471517 | 0.78 | FUCA1 (0.45) | DRD2DRD3FUCA1SIGMAR1GRIN2B | |
| Hydrochloric Acid SCHEMBL22076642 | 0.77 | FUCA1 (0.44) | DRD2DRD3FUCA1SIGMAR1GRIN2B | |
| SCHEMBL705179 | 0.72 | FUCA1 (0.47) | DRD2DRD3FUCA1SIGMAR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | DRD2 701/4885DRD3 948/4885FUCA1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.